Page 4

TScan examines $100m IPO possibilities
The Alphabet, Astellas, Novartis and WuXi AppTec-backed T-cell cancer therapy developer has filed to list on the Nasdaq Global Market.
Vera Therapeutics vies for public markets spot
Alphabet and Merck Group could exit the immunological and inflammatory disease therapy developer in an offering with an $86.3m placeholder target.
Carlyle to capture Unchained Labs for $435m
Carlyle Group has agreed to pay $435m for the biologics research technology provider, which has raised $86m from investors including Novo.
Trinomab tracks series A funding
China Medical System and a WuXi Biologics industry investment fund were among the participants in the antibody therapy developer's $69.3m series A round.
Dynamk raises debut fund at $65m
Limited partners include drugs maker Pfizer, and healthcare-focused JSR Group and Lonza.
Daily Deal Round Up: April 26, 2021
Vehicle charging technology developer Virta has closed an Eneos-backed round at $36m while Hubert Burda-backed wealth manager StashAway pushed its total funding past $60m.
Impel NeuroPharma clinches $80m in IPO
3M-backed CNS disorder therapy developer Impel priced its initial public offering in the middle of its range, giving it a $290m market cap.
Hygea ties up $77m series C
SenseTime and Sinopharm Capital have contributed to the oncology surgical device developer’s latest round, which will fund sales, marketing, product and technology improvement.
Daily Deal Round Up: April 23, 2021
Okta Ventures contributed to a $60m round for device management platform developer Kandji while real estate data provider Cherre raised $50m from investors including Intel Capital.
NeuroPace nets $102m in IPO
The Medtronic and Johnson & Johnson-backed epilepsy treatment system provider floated at the top of its range and saw its shares rise 47% on their first day.

test reg